Sevelamer 인결합제와 투석환자의 Chronic Kidney Disease-Mineral Bone Disorder 관리
Management of Chronic Kidney Disease-Mineral Bone Disorder with Sevelamer Hcl Phosphate binder in Korean Patients with Dialysis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Sevelamer is associated with reduced complications of chronic kidney disease-mineral bone disorder (CKD-MBD) resulted from hyperphosphatemia, which may contribute mortality, in CKD patients with dialysis. So far clinical outcomes of sevelamer on mortality and risk of cardiovascular mortality related to CKD-MBD are debating. Purpose of this study was to evaluate the effectiveness of sevelamer HCl on mortality of secondary hyperparathyroidism (SHPT), risk of cardiovascular mortality and, frequency of osteopathy in end stage renal disease (ESRD) patients with dialysis. Methods: We retrospectively reviewed the electronic medical records of 536 patients with ESRD, who were admitted for moderate to severe SHPT, for 36 months. 75 patients who met inclusion criteria were evaluated for the efficacy of sevelamer (mean serum iPTH = 487.5 pg/mL). Results: Sevelamer intervention was not associated with increased three-year survival time compared with non-sevelamers group [average survival month: 30.4 months in sevelamer group, 26.8 months in non-sevelamer group, p = 0.463]. Sevelamer intervention was not associated with significant mortality benefit and cardiovascular mortality benefit as compared to non-sevelamer group [sevelamer group: non-sevelamer group, all-cause mortality (iPTH > 600 pg/mL): 14.3% (1/34): 20% (1/41) p = 0.962, OR = 0.935, 95% CI, 0.058-14.98, heart disease mortality: 6.67% (2/30): 0% (0/32) p = 0.138]. Sevelamer was not associated with significantly lower cumulative incidence of osteopathy compared to non-sevelamer group (sevelamer group: non-sevelamer group, 5.9% (2/34):9.8% (4/41); p = 0.538; OR = 0.578; 95% CI, 0.099-3.367). Conclusion: Sevelamer was not associated with decreased all-cause mortality and risk of cardiovascular mortality compared to non-sevelamer group in ESRD patients with SHPT.
Abstract
Background: Sevelamer is associated with reduced complications of chronic kidney disease-mineral bone disorder (CKD-MBD) resulted from hyperphosphatemia, which may contribute mortality, in CKD patients with dialysis. So far clinical outcomes of sevelamer on mortality and risk of cardiovascular mortality related to CKD-MBD are debating. Purpose of this study was to evaluate the effectiveness of sevelamer HCl on mortality of secondary hyperparathyroidism (SHPT), risk of cardiovascular mortality and, frequency of osteopathy in end stage renal disease (ESRD) patients with dialysis. Methods: We retrospectively reviewed the electronic medical records of 536 patients with ESRD, who were admitted for moderate to severe SHPT, for 36 months. 75 patients who met inclusion criteria were evaluated for the efficacy of sevelamer (mean serum iPTH = 487.5 pg/mL). Results: Sevelamer intervention was not associated with increased three-year survival time compared with non-sevelamers group [average survival month: 30.4 months in sevelamer group, 26.8 months in non-sevelamer group, p = 0.463]. Sevelamer intervention was not associated with significant mortality benefit and cardiovascular mortality benefit as compared to non-sevelamer group [sevelamer group: non-sevelamer group, all-cause mortality (iPTH > 600 pg/mL): 14.3% (1/34): 20% (1/41) p = 0.962, OR = 0.935, 95% CI, 0.058-14.98, heart disease mortality: 6.67% (2/30): 0% (0/32) p = 0.138]. Sevelamer was not associated with significantly lower cumulative incidence of osteopathy compared to non-sevelamer group (sevelamer group: non-sevelamer group, 5.9% (2/34):9.8% (4/41); p = 0.538; OR = 0.578; 95% CI, 0.099-3.367). Conclusion: Sevelamer was not associated with decreased all-cause mortality and risk of cardiovascular mortality compared to non-sevelamer group in ESRD patients with SHPT.
참고문헌 (39)
- Block GA, "How should hyperphosphatemia be managed in dialysis patients", Semin Dial, 15, pp.315~317 (2002)
- Block GA, "Mineral metabolism, mortality, and morbidity in maintenance hemodialysis", J Am Soc Nephrol, 15, pp.2208~2218 (2004)
- Kestenbaum B, "Phosphate metabolism in the setting of chronic kidney disease: Significance and recommendations for treatment", Semin Dial, 20(4), pp.286~294 (2007)
- Amann K, "Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia", Kidney Int, 63, pp.1296~1301 (2003)
- Mathew S, "The mechanism of phosphorus as a cardiovascular risk factor in CKD", J Am Soc Nephrol, 19, pp.1092~1105 (2008)
- Toussaint ND, "Phosphate in early chronic kidney disease: Associations with clinical outcomes and a target to reduce cardiovascular risk", Nephrolo, 17, pp.433~444 (2012)
- Fukagawa M, "CKD-MBD guideline working group, clinical practice gfor the management of chronic kidney disease-mineral and bone disorder", Ther Apher Dial, 17(3), pp.247~288 (2013)
- Elder G, "Pathophysiology and recent advances in the management of renal osteodystrophy", J Bone Miner Res, 17, pp.2094~2105 (2002)
- Fukagawa M, "CKD-MBD guideline working group; Japanese society 2 for dialysis therapy. Clinical practice guideline for the management of chronic kidney disease mineral and bone disorder", Ther Apher Dial, 17(3), pp.247~288 (2013)
- Levin A, "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease", Kidney Int, 71, pp.31~38 (2007)
- Wills MR, "Aluminum poisoning: dialysis encephalopathy, osteomalacia and anemia", Lancet, 2, pp.29~34 (1983)
- Block GA, "A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease:A new paradigm for clinical outcomes studies in nephrology", Hemodial Int, 13, pp.360~362 (2009)
- Tonelli M, "Oral phosphate binders in patients with Kidney failure", New EngL J Med, 362, pp.1312~1324 (2010)
- Suki WN, "Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients", Kidney Int, 72, pp.1130~1137 (2007)
- Block GA, "Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients", Kidney Int, 71, pp.438~441 (2007)
- Panichi V, "Impact of calcium, phosphate, PTH abnormalities and management on mortality in hemodialysis:results from the RISCAVID study", J Nephrol, 23, pp.556~562 (2010)
- National Kidney Foundation, "K", DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease, 2003, pp.42(Suppl 3), S1~S201
- National collaborating centre for chronic conditions, "Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care" (2008), Royal College of physicians (UK)
- The kidney disease: Improving global outcomes (KDIGO) work group, "KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)", Kidney Int, 113, pp.S1~S130 (2009)
- Stuatevant JM, "Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders", Nephrol, 9, pp.406~413 (2004)
- Marangon N, "Nonphosphate-binding effects of sevelamer—Are they of clinical relevance?", Semin Dial, 21, pp.385~389 (2008)
- Adeney KL, "Association of serum phosphate with vascular and valvular calcification in moderate CKD", J Am Soc Nephrol, 20, pp.381~387 (2009)
- Dhingra R, "Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community", Arch. Int. Med, 167, pp.879~885 (2007)
- Braun J, "Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients", Am J Kidney Dis, 27, pp.394~401 (1996)
- Patel L, "Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: A meta-analysis of randomized controlled trials", Clin J Am Soc Nephrol, 11, pp.232~244 (2016)
- Wang C, "New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients: A meta-analysis of randomized controlled trials", PLoS One, 10(7), pp.e0133938~ (2015)
- Danese MD, "PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis", Am J Kidney Dis, 47, pp.149~156 (2006)
- Floege J, "Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population", Nephrol Dial Transplant, 26, pp.1948~1955 (2011)
- Jean G, "Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients:Results from the French ARNOS study", Hemodial Int, 15, pp.485~492 (2011)
- Liu L, "The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a metaanalysis of randomized trials", Ren Fail, 36, pp.1244~1252 (2014)
- Locatelli F, "Cardiovascular mortality in chronic kidney disease patients: potential mechanisms and possibilities of inhibition by resin-based phosphate binders", Expert Rev Cardiovasc Ther, 13, pp.489~499 (2015)
- Chertow GM, "Determinants of progressive vascular calcification in haemodialysis patients", Nephrol Dial Transplant, 19, pp.1489~1496 (2004)
- Chiu Y-W, "Coronary artery calcification and mortality in diabetic patients with proteinuria", Kidney Int, 77, pp.1107~1114 (2010)
- Isakova T, "Phosphorus binders and survival on hemodialysis", J. Am. Soc. Nephrol, 20, pp.388~396 (2009)
- Lin Y-F, "Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients", J Formos Med Assoc, 109, pp.663~672 (2010)
- Navaneethan SD, "Benefits and harms of phosphate binders in CKD: A systematic review of randomized controlled trials", Am J Kidney Dis, 54, pp.619~637 (2009)
- Soroka SD, "Mineral metabolism management in Canadian peritoneal dialysis patients", Clin Nephrol, 75, pp.410~415 (2011)
- Ogata H, "Therapeutic strategies for secondary hyperparathyroidism in dialysis patients", Ther Apher Dial, 10, pp.355~364 (2006)
- Menon V, "Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study", Am J Kidney Dis, 53, pp.208~217 (2009)